BPC-157 and TB-500 are often marketed together as "repair peptides," and they are constantly discussed together — in forums, in marketing copy, and in the same vial as a blended research product. That pairing creates a false impression of kinship. In reality they are unrelated molecules with separate research literatures, and one fact should frame everything below: the cited literature does not establish a randomized head-to-head comparison or a combination advantage. Every comparison on this page is a comparison of two bodies of literature, not of two arms of an experiment.
The second framing fact: both evidence bases are essentially preclinical. BPC-157 has no published controlled human trials at all. TB-500 itself has none either; human studies of full-length thymosin beta-4 (Tβ4) include eye drops, intravenous safety research and a small topical venous-ulcer trial [19][23][24] — evidence for a different molecule. Neither compound is an approved drug anywhere, and both are prohibited at all times for athletes. For full study indexes, see the individual pages: BPC-157: Research Overview & Study Index and TB-500: Research Overview & Study Index.
Side-by-side comparison
| BPC-157 | TB-500 | |
|---|---|---|
| Origin / molecule class | Synthetic 15-amino-acid fragment of a protein reported in human gastric juice ("Body Protection Compound") [1] | Product name from the veterinary/gray market; analyzed products contained Ac-LKKTETQ, a synthetic 7-amino-acid fragment (residues 17–23, the actin-binding segment) of the natural 43-amino-acid peptide thymosin beta-4 [20,21] |
| Proposed mechanism | Angiogenesis via VEGFR2–Akt–eNOS signaling [4]; fibroblast migration via FAK–paxillin [5]; modulation of the nitric-oxide system [3]. No receptor identified. | Sequestration of monomeric G-actin, regulating cytoskeletal assembly and cell migration [12,13]; the LKKTET motif proposed as the "active" segment [16]. No receptor established. |
| Research models studied | Rodent tendon, ligament, and muscle injury; GI ulceration, colitis, and fistula models; vascular occlusion models [3,6,7,8,9,10] | Rodent dermal wounds [14,15], mouse cardiac injury [17,18], corneal injury, and hair growth [15,16] — nearly all conducted with full-length Tβ4, not the TB-500 fragment |
| Human-trial status | No established controlled human efficacy; a small retrospective report exists [22]. A 1990s inflammatory bowel disease program (Pliva) reportedly reached early-phase testing, but controlled results were never published [2] | No published human trials of TB-500 itself. Full-length Tβ4 eye drops (RGN-259) have small ophthalmic trials: phase 2 signals and a small phase 3 neurotrophic keratopathy trial whose primary four-week healing comparison was not statistically significant (p=0.0656), despite later and secondary findings favoring treatment [19]. A European phase 3 trial missed its primary endpoint in 2025 |
| Doping status | Prohibited at all times — WADA Section S0 (Non-Approved Substances) | Prohibited at all times — WADA Section S2 (Peptide Hormones, Growth Factors); detection methods in routine laboratory use [20,21] |
| Evidence depth | Hundreds of animal publications, but a large majority from one laboratory (University of Zagreb); independent replication thin; a 2025 systematic review flags risk of bias [11] | Preclinical literature belongs mostly to parent Tβ4, largely from NIH-affiliated groups; the 7-amino-acid fragment itself has almost no direct study outside doping-control chemistry [20,21] |
| Regulatory status | Not approved anywhere; FDA compounding status "nominated but withdrawn" — a gray zone, not an authorization | Not approved anywhere; RGN-259 (full-length Tβ4) remains investigational |
Two different mechanisms, two different molecules
Mechanistically, these peptides have essentially nothing in common beyond the word "healing" in their literatures.
BPC-157 is a gastric pentadecapeptide — a stable synthetic fragment of a protein its discoverers reported isolating from human gastric juice, framed from the start within a "stomach-stress-organoprotection" hypothesis [1]. Its proposed activities cluster around blood-vessel formation and injury signaling: an independent Taiwanese group associated it with VEGFR2 activation and endothelial tube formation [4], cell-culture work associated it with tendon-fibroblast migration through FAK–paxillin phosphorylation [5], and the originating laboratory has built a broad program around its interactions with the nitric-oxide system [3]. No receptor has been identified.
TB-500 is an actin-binding fragment of thymosin beta-4. Tβ4 is one of the most abundant intracellular peptides in mammalian cells, and its defining role is biochemical housekeeping: binding monomeric G-actin one-to-one and holding it in an unpolymerized pool, which is central to how cells remodel their cytoskeleton to move [12,13]. Because cell migration is an early step in wound repair, researchers hypothesized a healing role for Tβ4 [13], and peptide-mapping work reported that short peptides containing the LKKTET actin-binding motif reproduced some activities in rodent assays [16]. That motif is what analyzed TB-500 products contain — a seven-amino-acid piece of a 43-amino-acid molecule [20,21]. Whether the fragment reproduces the parent peptide's biology is, for nearly every finding, untested.
What the animal models actually show — and where they overlap
The two literatures overlap on paper in tendon, wound, and muscle research, but the underlying experiments are different in kind.
BPC-157's musculoskeletal literature is direct but concentrated. Rat studies associated BPC-157 administration with faster healing of transected Achilles tendon [6], improved medial collateral ligament repair over 90 days [7], and better functional and histological recovery in transected and crushed muscle [8,9]. The GI literature — ulceration, colitis, and fistula models — is the largest single share and reflects the compound's gastric origin [10]. The catch: most of this comes from one research group, and a 2025 systematic review by outside authors concluded the animal findings are consistently positive but carry meaningful risk-of-bias concerns and include only limited, uncontrolled human observations [11][22].
TB-500's literature mostly is not TB-500's literature. The wound-healing findings — accelerated closure and re-epithelialization in rat full-thickness wounds [14], angiogenesis and repair in aged animals [15] — used full-length Tβ4. So did the two influential Nature papers on mouse cardiac injury [17,18], the corneal models that led to human eye-drop trials, and the rodent hair-growth work [15,16]. The fragment itself appears in the peer-reviewed record chiefly through doping-control chemistry: the Hong Kong racing laboratory that identified it in a marketed product [20] and the Ghent group that synthesized it as reference material [21]. Extrapolating those Tβ4 findings to TB-500 is an assumption stacked on an assumption.
The credibility caveat each one carries
Each compound has a distinctive weakness that a careful reader should keep in front of them.
BPC-157: single-laboratory concentration. A large majority of its hundreds of publications come from one group at the University of Zagreb with heavily overlapping author lists. Independent replication exists — the Taiwanese angiogenesis and tendon-cell studies are the notable examples [4,5] — but it is thin, and unreplicated findings warrant caution regardless of how numerous they are [11].
TB-500: molecule identity. "TB-500" is a market name, not a scientific one. Doping-control analyses identified the constituent as the acetylated 17–23 fragment of Tβ4 [20,21], but the market is unregulated, some vials may contain full-length Tβ4 or other mixtures, and no manufacturing standard exists. When a product's identity is uncertain, attaching any literature to it — even the preclinical kind — gets slippery.
Why they are researched together
The pairing is commercial and thematic, not scientific. Both compounds circulate in the research-chemical market under the "tissue repair" banner, both appear in the same forum discussions, and suppliers sell them combined in blend products (this catalog's blend listing is an example of the category). That coexistence is the entire basis of the pairing.
A small retrospective knee-pain report included BPC-157 alone and BPC-157 with reported thymosin beta-4 [22]. It does not establish the identity of a commercial TB-500 fragment, isolate a combination effect or demonstrate synergy. Acknowledging that report is different from treating it as controlled evidence for the marketed blend.
Bottom line
There is no evidence-based answer to "BPC-157 or TB-500" because the comparative experiment does not exist and neither compound has cleared the bar of published controlled human data. What the record supports is narrower: BPC-157 has a large but laboratory-concentrated rodent literature across musculoskeletal, GI, and vascular injury models [3,6,7,8,9,10,11]; TB-500 borrows its reputation from full-length thymosin beta-4's preclinical record and a small, mixed set of ophthalmic trials that used a different molecule and route entirely [14,15,17,18,19]. Both are unapproved, both are prohibited in sport, and both remain research compounds in the strict sense of the word.
References
Sikirić P, Petek M, Ručman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-327. doi:10.1016/0928-4257(93)90038-U — PMID: 8298609
Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14(5-6):214-221. doi:10.1007/s10787-006-1531-7 — PMID: 17186181
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126-1135. doi:10.2174/13816128113190990411 — PMID: 23755725
Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y — PMID: 27847966
Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010 — PMID: 21030672
Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4 — PMID: 14554208
Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. doi:10.1002/jor.21107 — PMID: 20225319
Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res. 2006;24(5):1109-1117. doi:10.1002/jor.20089 — PMID: 16609979
Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716-725. doi:10.1007/s00595-007-3706-2 — PMID: 18668315
Sikiric P, Skrtic A, Gojkovic S, et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection. Inflammopharmacology. 2024;32(5):3119-3161. doi:10.1007/s10787-024-01499-8 — PMID: 38980576
Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. doi:10.1177/15563316251355551 — PMID: 40756949
Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. doi:10.1016/S0021-9258(20)64278-8 — PMID: 1999398
Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004 — PMID: 16099219
Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x — PMID: 10469335
Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. doi:10.1016/j.mad.2003.11.005 — PMID: 15037013
Philp D, St-Surin S, Cha HJ, et al. Thymosin beta 4 induces hair growth via stem cell migration and differentiation. Ann N Y Acad Sci. 2007;1112:95-103. doi:10.1196/annals.1415.009 — PMID: 17947589
Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000 — PMID: 15565145
Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. doi:10.1038/nature05383 — PMID: 17108969
Sosne G, Kleinman HK, Springs C, et al. 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2022;24(1):554. doi:10.3390/ijms24010554 — PMID: 36613994
Ho ENM, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. doi:10.1016/j.chroma.2012.09.043 — PMID: 23084823
Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. doi:10.1002/dta.1402 — PMID: 22962027
Lee E, et al. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435
Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-9. doi:10.1111/j.1749-6632.2010.05474.x. PMID: 20536472
Guarnera G, et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207-12. doi:10.1111/j.1749-6632.2010.05490.x. PMID: 20536470
This article is an educational summary of published research. It is not medical advice, and it does not describe, endorse, or recommend any use of BPC-157, TB-500, or thymosin beta-4 in humans. Neither compound is an approved drug. Products referenced on this site are sold for laboratory research use only.